Učitavanje...

Sorafenib: Experience and Better Manage­ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis

BACKGROUND: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life, if this translates into a better prognosis. METHODS: This was a retrospective study of advanced HCC patients treat...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Liver Cancer
Glavni autori: Raoul, Jean-Luc, Adhoute, Xavier, Penaranda, Guillaume, Perrier, Hervé, Castellani, Paul, Oules, Valérie, Bourlière, Marc
Format: Artigo
Jezik:Inglês
Izdano: S. Karger AG 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883434/
https://ncbi.nlm.nih.gov/pubmed/31799203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000497161
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!